17Mar 2023
Could Platelet LGALS3BP be the key to unlocking new Lupus treatments?

Could Platelet LGALS3BP be the key to unlocking new Lupus treatments?

Researchers investigated the role of platelet-associated lectin, galactoside-binding, soluble 3-binding protein (LGALS3BP) as a mediator of inflammation in systemic lupus erythematosus (SLE) and as a potential biomarker associated with clinical phenotypes. Platelets from patients with SLE had increased expression of LGALS3BP, and their levels were correlated with the severity of the disease according to the SLE Disease Activity Index. Circulating LGALS3BP levels were higher in SLE patients with lupus nephritis than in patients with inactive disease. Interferon-α induced LGALS3BP transcription and translation in a megakaryoblastic cell line, and LGALS3BP enhanced proinflammatory cytokine production by macrophages. Platelets are potent effector cells that contribute to the pathogenesis of SLE by secreting proinflammatory LGALS3BP, which also represents a novel biomarker of SLE clinical activity.

  • #rheumatology

Like

Save

Share